Behavioral and morphological effects of resveratrol and curcumin in rats submitted to doxorubicin-induced cognitive impairment

Doxorubicin (DOX) is known to cause cognitive impairments in patients submitted to long-term chemotherapy (deficits also known as chemobrain). Therefore, there is an urgent need for therapeutic strategies capable of returning cancer survivors back to their previous quality of life. The present study...

Full description

Saved in:

Bibliographic Details
Published in:	Research in veterinary science Vol. 140; pp. 242 - 250
Main Authors:	Moretti, R.L., Dias, E.N., Kiel, S.G., Augusto, M.C.M., Rodrigues, P.S., Sampaio, A.C.S., Medeiros, L.S., Martins, M.F.M., Suffredini, I.B., Cardoso, C.V., Bondan, E.F.
Format:	Journal Article
Language:	English
Published:	Oxford Elsevier Ltd 01-11-2021 Elsevier Limited
Subjects:	Animal cognition Astrocytes Brain Chemotherapy Cognitive ability Cortex (frontal) Curcumin Cytokines Demyelination Distilled water Doxorubicin Glial fibrillary acidic protein Gliosis Habituation Habituation (learning) Hypothalamus Immunohistochemistry Laboratory animals Long term memory Memory Memory impairment Microglia Morphology Nonsteroidal anti-inflammatory drugs Object recognition Pattern recognition Quality of life Resveratrol Saline solutions Veterinary medicine St Louis Missouri Brazil United States > US Memory impairment Chemotherapy Astrocytes Glial fibrillary acidic protein Microglia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Doxorubicin (DOX) is known to cause cognitive impairments in patients submitted to long-term chemotherapy (deficits also known as chemobrain). Therefore, there is an urgent need for therapeutic strategies capable of returning cancer survivors back to their previous quality of life. The present study investigated whether resveratrol (RSV) or curcumin (CUR) administration could affect mnemonic function and brain morphological changes following DOX administration in rats. Male Wistar rats were divided into 4 groups: DOX group (2.5 mg/kg/week for 4 weeks, i.p., plus distilled water for 28 days, oral gavage - OG), DOX + RSV group (DOX, 2.5 mg/kg/week for 4 weeks, i.p., plus RSV, 10 mg/kg/day for 28 days, OG), DOX + CUR group (DOX, 2.5 mg/kg/week for 4 weeks, i.p., plus CUR, 100 mg/kg/day for 28 days, OG) and control (CTR) group (0.9% saline solution weekly for 4 weeks, i.p., plus distilled water for 28 days, OG). Behavioral analyses (open field - OF - and the novel object recognition test - NORT) were performed. Brains were collected and analyzed by hematoxylin-eosin and luxol fast blue staining techniques and by immunohistochemistry for GFAP (glial fibrillary acidic protein) expression in astrocytes and Iba1 (ionized calcium-binding adaptor molecule 1) expression in microglia. DOX-injected rats presented short-term and long-term memory impairments as seen in the NORT at 3 and 24 h after habituation and increased GFAP and Iba1 expression, respectively, in astrocytes and microglia of the frontal cortex, hypothalamus and hippocampus. Such cognitive deficits were prevented by CUR at both periods and by RSV at 24 h. DOX-induced astrogliosis and microgliosis were avoided by RSV and CUR. No signs of demyelination or neuronal loss were found in any group. Thus, CUR and RSV prevented memory loss, astrogliosis and microgliosis induced by DOX monotherapy. •Doxorubicin administration impaired short-term and long-term memory in rats, but not locomotor activity.•Expression of GFAP and Iba1 was increased by doxorubicin in the frontal cortex, hypothalamus and hipoccampus.•Resveratrol and curcumin prevented doxorubicin-induced astrogliosis and microgliosis.•Curcumin prevented short- and long-term memory deficits caused by doxorubicin.•Resveratrol avoided only the long-term memory impairments induced by doxorubicin.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0034-5288 1532-2661
DOI:	10.1016/j.rvsc.2021.09.009